Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01081782 · ClinicalTrials.gov registry record · Phase 2
A Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
A Phase 2 study of Multiple Sclerosis, sponsored by Ono Pharma USA.
- Completed
- Registry status
- Phase 2
- Development phase
- 407
- Enrollment target
- 20
- Study locations
NCT01081782 is a Phase 2 study of Multiple Sclerosis that has completed, run by Ono Pharma USA. The registered enrollment target is 407 participants, below the 584-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (30% lower). The trial reports 20 study locations across 13 states.
The verdict
NCT01081782, a Phase 2 study of Multiple Sclerosis, has completed, sponsored by Ono Pharma USA.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 407 participants
- Enrollment target
- 20
- Study locations
Study Summary
The objective of this study is to evaluate the safety and efficacy of ONO-4641 in patients with relapsing-remitting multiple sclerosis over a 26-week treatment period.
Conditions Studied
Interventions
- DRUG ONO-4641
- DRUG ONO-4641 placebo
Study Locations (20)
Florida
- Ormond Beach Clinical Site 129 - Ormond Beach
- Sarasota Clinical Site 116 - Sarasota
- Sarasota Clinical Site 117 - Sarasota
North Carolina
- Charlotte Clinical Site 125 - Charlotte
- HighPoint Clinical Site 128 - HighPoint
- Raleigh Clinical Site 103 - Raleigh
Colorado
- Aurora Clinical Site 132 - Aurora
- Fort Collins Clinical Site 123 - Fort Collins
Indiana
- Fort Wayne Clinical Site 111 - Fort Wayne
- Indianapolis Clinical Site 121 - Indianapolis
Michigan
- Detroit Clinical Site 104 - Detroit
- Farmington Hills Clinical Site 126 - Farmington Hills
Arizona
- Tucson Clinical Site 133 - Tucson
Connecticut
- Fairfield Clinical Site 110 - Fairfield
Illinois
- Northbrook Clinical Site 135 - Northbrook
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 407 participants |
| Start Date | 2010-03 |
| Est. Completion | 2011-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01081782
The ClinicalTrials.gov registry entry for NCT01081782 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 407 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 584-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (30% lower). The listed sponsor is Ono Pharma USA, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Sclerosis appearing as the primary indexed condition, and to 2 interventions - of which ONO-4641 is the first listed.
NCT01081782 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Florida, North Carolina, Colorado.
Frequently Asked Questions
What is clinical trial NCT01081782 about?
NCT01081782 is a clinical study titled "A Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis". The objective of this study is to evaluate the safety and efficacy of ONO-4641 in patients with relapsing-remitting multiple sclerosis over a 26-week treatment period.
What is the current status of trial NCT01081782?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 407 participants. The study started on 2010-03. Estimated completion is 2011-12.
What conditions does trial NCT01081782 study?
This clinical trial studies the following conditions: Multiple Sclerosis.
What interventions are being tested in trial NCT01081782?
The interventions under investigation include: ONO-4641 (DRUG), ONO-4641 placebo (DRUG).
Who is sponsoring clinical trial NCT01081782?
This trial is sponsored by Ono Pharma USA, which has 17 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01081782 being conducted?
This trial has 20 study locations across Arizona, Colorado, Connecticut, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Mechanisms of Cannabidiol in Persons With MS: the Role of Sleep and Pain Phenotype
RECRUITING · Phase 2
-
Metformin as an add-on or Monotherapy in Treatment of Aging People With Multiple Sclerosis (MS)
RECRUITING · Phase 2
-
A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)
RECRUITING · Phase 2
-
Solriamfetol for the Treatment of Multiple Sclerosis Fatigue
RECRUITING · Phase 2
-
A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years
RECRUITING · Phase 2
-
Efficacy of Cognitive Behavioral Therapy for Insomnia to Treat Insomnia Symptoms in Individuals With Multiple Sclerosis
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.